日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

综合 CRISPR 筛选和药物分析可确定 EGFR、ALK 和 BRAF/MEK 抑制剂的联合用药机会

Ralph Tiedt, Frederick J King, Christelle Stamm, Matthew J Niederst, Scott Delach, Sabine Zumstein-Mecker, Jodi Meltzer, Iain J Mulford, Emma Labrot, Barbara Schacher Engstler, Sabrina Baltschukat, Grainne Kerr, Javad Golji, Daniel Wyss, Christian Schnell, Edward Ainscow, Jeffrey A Engelman, William

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

LXH254 是一种强效且选择性的 BRAF 和 CRAF 抑制剂,用于治疗 MAPK 驱动的肿瘤

Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy Higgins, Hui Qin Wang, Jinsheng Liang, Karen Bui, John Green, Peter Aspesi, Jessi Ambrose, Felipa Mapa, Lesley Griner, Mariela Jaskelioff, John Fuller, Kenneth Crawford, Gwynn Pardee, S

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

靶向FGFR可克服EGFR突变型非小细胞肺癌中EMT介导的耐药性

Sana Raoof ,Iain J Mulford ,Heidie Frisco-Cabanos ,Varuna Nangia ,Daria Timonina ,Emma Labrot ,Nafeeza Hafeez ,Samantha J Bilton ,Yotam Drier ,Fei Ji ,Max Greenberg ,August Williams ,Krystina Kattermann ,Leah Damon ,Sosathya Sovath ,Daniel P Rakiec ,Joshua M Korn ,David A Ruddy ,Cyril H Benes ,Peter S Hammerman ,Zofia Piotrowska ,Lecia V Sequist ,Matthew J Niederst ,Jordi Barretina ,Jeffrey A Engelman ,Aaron N Hata

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

SHP2 抑制可恢复对 ALK 抑制剂有耐药性的 ALK 重排非小细胞肺癌的敏感性

Leila Dardaei, Hui Qin Wang, Manrose Singh, Paul Fordjour, Katherine X Shaw, Satoshi Yoda, Grainne Kerr, Kristine Yu, Jinsheng Liang, Yichen Cao, Yan Chen, Michael S Lawrence, Adam Langenbucher, Justin F Gainor, Luc Friboulet, Ibiayi Dagogo-Jack, David T Myers, Emma Labrot, David Ruddy, Melissa Park